Regulus Therapeutics Inc. (RGLS)
NASDAQ: RGLS · Real-Time Price · USD
2.550
+0.230 (9.91%)
At close: Apr 23, 2025, 4:00 PM
2.530
-0.020 (-0.78%)
After-hours: Apr 23, 2025, 5:40 PM EDT
Regulus Therapeutics Employees
Regulus Therapeutics had 34 employees as of December 31, 2024. The number of employees increased by 4 or 13.33% compared to the previous year.
Employees
34
Change (1Y)
4
Growth (1Y)
13.33%
Revenue / Employee
n/a
Profits / Employee
-$1,363,471
Market Cap
168.92M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
RGLS News
- 21 days ago - Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit - PRNewsWire
- 27 days ago - Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease - Benzinga
- 27 days ago - Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - PRNewsWire
- 5 weeks ago - Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates - PRNewsWire
- 7 weeks ago - Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference - PRNewsWire
- 2 months ago - Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - PRNewsWire
- 3 months ago - Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429) - PRNewsWire
- 5 months ago - Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences - PRNewsWire